Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen

Charles Williams Flexner, Brian R. Murphy, James F. Rooney, Charles Wohlenberg, Vadim Yuferov, Abner L. Notkins, Bernard Moss

Research output: Contribution to journalArticle

Abstract

A global vaccination strategy must take into account production and delivery costs as well as efficacy and safety. A heat-stable, polyvalent vaccine that requires only one inoculation and induces a high level of humoral and cellular immunity against several diseases is therefore desirable. A new approach is to use live microorganisms such as mycobacteria1, enteric bacteria2,3, adenoviruses4, herpes viruses5,6 and poxviruses7 as vaccine vectors. A potential limitation of live polyvalent vaccines, however, is existing immunity within the target population not only to the vector, but to any of the expressed antigens. This could restrict replication of the vector, curtail expression of antigens, and reduce the total immune response to the vaccine. Recently acquired immunity to vaccinia virus can severely limit the efficacy of a live recombinant vaccinia-based vaccine8, so a strategy involving closely spaced inoculations with the same vector expressing different antigens may present difficulties. We have constructed a recombinant vaccinia virus that expresses surface proteins from two diverse pathogens, influenza A virus haemagglutinin and herpes simplex virus type 1 (HSV-1) glycoprotein D. Mice that had recently recovered from infection with either HSV-1 or influenza A virus could still be effectively immunized with the double recombinant.

Original languageEnglish (US)
Pages (from-to)259-262
Number of pages4
JournalNature
Volume335
Issue number6187
StatePublished - 1988
Externally publishedYes

Fingerprint

Immunity
Vaccination
Vaccines
Antigens
Vaccinia virus
Influenza A virus
Human Herpesvirus 1
Vaccinia
Health Services Needs and Demand
Hemagglutinins
Adaptive Immunity
Humoral Immunity
Cellular Immunity
Glycoproteins
Membrane Proteins
Hot Temperature
Safety
Costs and Cost Analysis
Infection

ASJC Scopus subject areas

  • General

Cite this

Flexner, C. W., Murphy, B. R., Rooney, J. F., Wohlenberg, C., Yuferov, V., Notkins, A. L., & Moss, B. (1988). Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen. Nature, 335(6187), 259-262.

Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen. / Flexner, Charles Williams; Murphy, Brian R.; Rooney, James F.; Wohlenberg, Charles; Yuferov, Vadim; Notkins, Abner L.; Moss, Bernard.

In: Nature, Vol. 335, No. 6187, 1988, p. 259-262.

Research output: Contribution to journalArticle

Flexner, CW, Murphy, BR, Rooney, JF, Wohlenberg, C, Yuferov, V, Notkins, AL & Moss, B 1988, 'Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen', Nature, vol. 335, no. 6187, pp. 259-262.
Flexner CW, Murphy BR, Rooney JF, Wohlenberg C, Yuferov V, Notkins AL et al. Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen. Nature. 1988;335(6187):259-262.
Flexner, Charles Williams ; Murphy, Brian R. ; Rooney, James F. ; Wohlenberg, Charles ; Yuferov, Vadim ; Notkins, Abner L. ; Moss, Bernard. / Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen. In: Nature. 1988 ; Vol. 335, No. 6187. pp. 259-262.
@article{8471464c38d44551afbaa720812adab6,
title = "Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen",
abstract = "A global vaccination strategy must take into account production and delivery costs as well as efficacy and safety. A heat-stable, polyvalent vaccine that requires only one inoculation and induces a high level of humoral and cellular immunity against several diseases is therefore desirable. A new approach is to use live microorganisms such as mycobacteria1, enteric bacteria2,3, adenoviruses4, herpes viruses5,6 and poxviruses7 as vaccine vectors. A potential limitation of live polyvalent vaccines, however, is existing immunity within the target population not only to the vector, but to any of the expressed antigens. This could restrict replication of the vector, curtail expression of antigens, and reduce the total immune response to the vaccine. Recently acquired immunity to vaccinia virus can severely limit the efficacy of a live recombinant vaccinia-based vaccine8, so a strategy involving closely spaced inoculations with the same vector expressing different antigens may present difficulties. We have constructed a recombinant vaccinia virus that expresses surface proteins from two diverse pathogens, influenza A virus haemagglutinin and herpes simplex virus type 1 (HSV-1) glycoprotein D. Mice that had recently recovered from infection with either HSV-1 or influenza A virus could still be effectively immunized with the double recombinant.",
author = "Flexner, {Charles Williams} and Murphy, {Brian R.} and Rooney, {James F.} and Charles Wohlenberg and Vadim Yuferov and Notkins, {Abner L.} and Bernard Moss",
year = "1988",
language = "English (US)",
volume = "335",
pages = "259--262",
journal = "Nature",
issn = "0028-0836",
publisher = "Nature Publishing Group",
number = "6187",

}

TY - JOUR

T1 - Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen

AU - Flexner, Charles Williams

AU - Murphy, Brian R.

AU - Rooney, James F.

AU - Wohlenberg, Charles

AU - Yuferov, Vadim

AU - Notkins, Abner L.

AU - Moss, Bernard

PY - 1988

Y1 - 1988

N2 - A global vaccination strategy must take into account production and delivery costs as well as efficacy and safety. A heat-stable, polyvalent vaccine that requires only one inoculation and induces a high level of humoral and cellular immunity against several diseases is therefore desirable. A new approach is to use live microorganisms such as mycobacteria1, enteric bacteria2,3, adenoviruses4, herpes viruses5,6 and poxviruses7 as vaccine vectors. A potential limitation of live polyvalent vaccines, however, is existing immunity within the target population not only to the vector, but to any of the expressed antigens. This could restrict replication of the vector, curtail expression of antigens, and reduce the total immune response to the vaccine. Recently acquired immunity to vaccinia virus can severely limit the efficacy of a live recombinant vaccinia-based vaccine8, so a strategy involving closely spaced inoculations with the same vector expressing different antigens may present difficulties. We have constructed a recombinant vaccinia virus that expresses surface proteins from two diverse pathogens, influenza A virus haemagglutinin and herpes simplex virus type 1 (HSV-1) glycoprotein D. Mice that had recently recovered from infection with either HSV-1 or influenza A virus could still be effectively immunized with the double recombinant.

AB - A global vaccination strategy must take into account production and delivery costs as well as efficacy and safety. A heat-stable, polyvalent vaccine that requires only one inoculation and induces a high level of humoral and cellular immunity against several diseases is therefore desirable. A new approach is to use live microorganisms such as mycobacteria1, enteric bacteria2,3, adenoviruses4, herpes viruses5,6 and poxviruses7 as vaccine vectors. A potential limitation of live polyvalent vaccines, however, is existing immunity within the target population not only to the vector, but to any of the expressed antigens. This could restrict replication of the vector, curtail expression of antigens, and reduce the total immune response to the vaccine. Recently acquired immunity to vaccinia virus can severely limit the efficacy of a live recombinant vaccinia-based vaccine8, so a strategy involving closely spaced inoculations with the same vector expressing different antigens may present difficulties. We have constructed a recombinant vaccinia virus that expresses surface proteins from two diverse pathogens, influenza A virus haemagglutinin and herpes simplex virus type 1 (HSV-1) glycoprotein D. Mice that had recently recovered from infection with either HSV-1 or influenza A virus could still be effectively immunized with the double recombinant.

UR - http://www.scopus.com/inward/record.url?scp=0023689085&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023689085&partnerID=8YFLogxK

M3 - Article

C2 - 2842693

AN - SCOPUS:0023689085

VL - 335

SP - 259

EP - 262

JO - Nature

JF - Nature

SN - 0028-0836

IS - 6187

ER -